Drug Profile

Tegaserod - Novartis

Alternative Names: HTF 919; SDZ HTF 919; Zelmac; Zelnorm

Latest Information Update: 04 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis
Developer Alfasigma; Novartis
Class Gastrokinetics; Indoles; Irritable bowel syndrome therapies
Mechanism of Action Serotonin 4 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Constipation; Irritable bowel syndrome
Discontinued Dyspepsia; Gastro-oesophageal reflux

Most Recent Events

30 Mar 2022 Withdrawn for Irritable bowel syndrome in USA (PO)
23 Jul 2020 Alfasigma and Indegene agree to co-promote tegaserod in USA for Irritable bowel syndrome
15 Aug 2019 Re-launched for Irritable bowel syndrome with constipation in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com